Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kalydeco ivacaftor regulatory update

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) deferred a reimbursement decision on Vertex's Kalydeco ivacaftor to allow the company time to submit a new

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE